Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (231-240 of 298) with videos related to

Pageof 30
Sort By:
Dermatology (Basel, Switzerland)|October 13, 2006
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.
Dermatology and Therapy|August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistryAlan Menter, Diamant Thaçi, Jashin J Wu, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Pediatric Dermatology|January 31, 2013
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United StatesKatherine Mercy, Mary Kwasny, Kelly M Cordoro, et al.
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
Pageof 30

Showing results (231-240 of 298) with videos related to

Sort By:
Pageof 30
Dermatology (Basel, Switzerland)|October 13, 2006
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.
Dermatology and Therapy|August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistryAlan Menter, Diamant Thaçi, Jashin J Wu, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Pediatric Dermatology|January 31, 2013
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United StatesKatherine Mercy, Mary Kwasny, Kelly M Cordoro, et al.
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
Pageof 30